Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.52 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569631 | 0.95 | MTNR1A (0.52) | MTNR1AMTNR1BPARP1ADRA2CTHRA | |
| SCHEMBL2565315 | 0.82 | OPRM1 (0.48) | — | |
| SCHEMBL19665946 | 0.79 | NPC1 (0.44) | MTNR1AMTNR1BPARP1THRATHRB | |
| SCHEMBL19665956 | 0.79 | NPC1 (0.44) | MTNR1AMTNR1BPARP1THRATHRB | |
| SCHEMBL2566701 | 0.79 | ACHE (0.46) | — | |
| SCHEMBL2560296 | 0.77 | OPRM1 (0.48) | — | |
| SCHEMBL294705 | 0.73 | PARP1 (0.55) | PARP1PARP10 | |
| SCHEMBL3110681 | 0.72 | PARP1 (0.50) | PARP1ADRA2CPARP10 | |
| SCHEMBL27473655 | 0.72 | THRA (0.42) | PARP1THRATHRB | |
| SCHEMBL14791423 | 0.72 | PRSS1 (0.62) | PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | MTNR1A 75/4885MTNR1B 37/4885PARP1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.